The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the ...

Participation of endothelin in salt-sensitive essential hypertension could be mediated by a deficit in its natriuretic actions, or by an exaggerated contribution to the control of vasoconstriction ...

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ischemia, vascular leakage, and microaneurysm count at 3 and 6 months in patients ...

Investigators at St. John’s University have published preclinical data regarding their endothelin-1 receptor (ETRA) antagonist HJP-272 for the potential treatment of cancer.

Endothelin-1 is a small vasoconstrictor peptide that was first identified in 1988. Here we review the evidence implicating ET-1 in tumorigenesis. In particular, we concentrate on the role of ET-1 ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

There is increasing evidence that endothelin-1 has a pathogenic role in pulmonary arterial hypertension 10 and that blockade of endothelin receptors may be beneficial. 11 Endothelin-1 is a potent ...

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Opsumit tablets, 10 mg, of ...

The dual endothelin-receptor antagonist macitentan was developed by modifying the structure of bosentan to increase efficacy and safety. 14 Macitentan is characterized by sustained receptor ...

Tezosentan a dual endothelin A/endothelin B receptor (ETA/ETB) blocker caused a dose-dependent increase in cardiac index ranging from 24.4% to 49.9%, versus 3% with placebo.

The Macitentan tablets, 10 mg, used to treat hypertension, have an estimated market size of $1,180 million for the 12 months till June 2025, as per IQVIA.